Evidence map›Paper›PMID 25604610›Full record

ArticleHIV medicine2015

Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.

J Rutstein Lazarus, R M Rutstein, E D Lowenthal

Open access · bronzeAbstract read
In one paragraph

Article in HIV medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

J Rutstein LazarusInstitute for Graduate Clinical Psychology, Widener University, Chester, PA, USA.
R M RutsteinSpecial Immunology Family Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
E D LowenthalSpecial Immunology Family Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Children's Hospital of Philadelphia · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Targeted Monitoring and Determinants of Adherence in Adolescents with HIVK23MH095669 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI LOWENTHAL, ELIZABETH DAWN · 2012 to 2016
$874k
NIAID NIH HHS P30 AI045008NIMH NIH HHS K23 MH095669
6 · The paper itself

Abstract

objectivesAlthough cognitive outcomes among perinatally infected youth have improved with highly active antiretroviral therapy (HAART), the impact of the age of initiation of treatment and the central nervous system (CNS) penetration effectiveness (CPE) of the regimen on cognitive outcomes is unknown. We aimed to describe the association between initiation age/regimen CPE score and cognitive outcomes in perinatally HIV-infected youth.

methodsLinear regression was used to retrospectively assess the association between full-scale IQ score (FSIQ) and age of initiation of HAART, regimen CPE, and the presence/absence of an AIDS diagnosis before initiation of HAART in an urban US cohort.

resultsA total of 88 of 181 subjects (48.6%) had an AIDS diagnosis. In 69, AIDS preceded the start of HAART. Mean FSIQ (mean age 155.4 months) was 86.3 [standard deviation (SD) 15.6]. Neither age of initiation of HAART (P = 0.45) nor regimen CPE score (P = 0.33) was associated with FSIQ. Mean FSIQ for patients with an AIDS diagnosis before HAART initiation [82 (SD 17.0)] was significantly lower than for patients initiating HAART before an AIDS diagnosis [90 (SD 13)] (P = 0.001). Of the 129 subjects without AIDS by age 5 years, 41 (31.8%) initiated HAART before age 5 years; four of 41 later developed AIDS, compared with 32 of 88 of those who did not initiate HAART before age 5 years. The relative risk of AIDS if HAART was initiated before age 5 years was 0.19 (95% confidence interval 0.05-0.60).

conclusionsEarlier age at HAART initiation and higher CPE score of a regimen did not improve cognitive outcomes. However, initiating HAART prior to AIDS protected against AIDS and was associated with a significantly higher FSIQ.

Indexed as

Antiretroviral Therapy, Highly ActiveHIV InfectionsInfectious Disease Transmission, VerticalAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsCD4 Lymphocyte CountChildChild, PreschoolCognition DisordersFemaleHumansIntelligenceLinear ModelsMaleRegression AnalysisAnti-HIV Agentsantiretroviral therapycentral nervous system penetration effectivenesscognitive outcomeHIV infection

Identifiers

PMID25604610
PMCPMC4478224
OpenAlexW2114093327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.